# MAUI Imaging

> MAUI Imaging is a Tucson medical-device company that reworks ultrasound from the signal-processing layer up. Its K3900 system uses a concave probe, unfocused acoustic pings and computational reconstruction to collect more paths through the body than conventional beam-line ultrasound. The $85,000 average-price system is FDA-cleared for broad traditional ultrasound uses, while MAUI and the U.S. military are studying its more unusual promise: useful images around bone, ribs, gas and other barriers in trauma settings where CT or MRI may be unavailable.

- **Founded:** 2006
- **Headquarters:** Tucson, United States
- **Founders:** David Specht (Co-founder and CEO), Don Specht (Co-founder and inventor)
- **Team size:** Business Insider reported eight employees and eight consultants in July 2025; LinkedIn lists the company in the 11-50 employee range.
- **Products:** K3900 Ultrasound Imaging System, Computed Echo Tomography, Clinical evaluation and workflow support
- **Notable:** Received FDA 510(k) clearance for the K3900 under K230511 on October 25, 2023., Built an intellectual-property portfolio reported as more than 160 granted U.S. and international patents, with dozens pending; a 2026 company release says more than 170 patents., Won a $4 million U.S. Department of Defense contract supporting trauma-medicine evaluation across four military branches.

## Products & services

- **K3900 Ultrasound Imaging System** — A portable Class II general-purpose ultrasound system comprising a transducer, processing unit and tablet interface. It uses Computed Echo Tomography and is FDA-cleared under K230511 for specified adult and pediatric B-mode applications.
- **Computed Echo Tomography** — MAUI's patented acquisition and reconstruction approach sends unfocused acoustic pings from multiple source groups, collects reflections across probe elements and computationally reconstructs the image while correcting for different paths and sound speeds.
- **Clinical evaluation and workflow support** — Demonstrations, studies and early deployments focused on trauma, neurology, critical care and interventional guidance; Acertara coordinates many U.S. hospital pre-orders, training, commissioning and post-market support.

## Achievements

- Received FDA 510(k) clearance for the K3900 under K230511 on October 25, 2023.
- Built an intellectual-property portfolio reported as more than 160 granted U.S. and international patents, with dozens pending; a 2026 company release says more than 170 patents.
- Won a $4 million U.S. Department of Defense contract supporting trauma-medicine evaluation across four military branches.
- Published a peer-reviewed 2025 baseline analysis in JACEP Open in which 59 of 65 predefined views were rated adequate for clinical decision-making.
- Raised a $14 million Series D led by Acertara Acoustic Laboratories in July 2025.
- Received a Gates Foundation grant to explore CET ultrasound for tuberculosis triage in resource-limited settings.

## Latest updates

- **2026-01** — MAUI announced a Gates Foundation-backed feasibility study using the K3900 for tuberculosis detection, diagnosis and triage; the foundation lists a $143,486 commitment from November 2025.
- **2025-07** — MAUI announced a $14 million Series D led by Acertara to fund production, sales and marketing; Acertara also took an exclusive U.S. hospital distribution role outside MAUI's direct accounts.
- **2025-05** — JACEP Open published the first peer-reviewed baseline analysis of K3900 trauma imaging, based on 65 views acquired in six healthy volunteers.
- **2024-08** — The company emerged from stealth and disclosed its $4 million Defense Department trauma-medicine contract.
- **2023-10** — The FDA found the K3900 substantially equivalent under the 510(k) pathway for its listed general-purpose ultrasound indications.

## Links

- Website: https://mauiimaging.com
- LinkedIn: https://www.linkedin.com/company/maui-imaging

---

Profile page: https://yespress.io/maui-imaging
Published by YesPress — https://yespress.io
Last updated: 2026-08-22